Literature DB >> 16079787

Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain.

Nathalie Ginovart1, Jeffrey H Meyer, Anahita Boovariwala, Doug Hussey, Eugenii A Rabiner, Sylvain Houle, Alan A Wilson.   

Abstract

This article describes the kinetic modeling of [(11)C]-harmine binding to monoamine oxidase A (MAO-A) binding sites in the human brain using positron emission tomography (PET). Positron emission tomography studies were performed in healthy volunteers at placebo conditions and after treatment with clinical doses of moclobemide. In either condition, a two-tissue compartment model (2CM) provided better fits to the data than a one-tissue model. Estimates of k(3)/k(4) values from an unconstrained 2CM were highly variable. In contrast, estimates of the specifically bound radioligand distribution volume (DV(B)) from an unconstrained 2CM were exceptionally stable, correlated well with the known distribution of MAO-A in the brain (cerebellum <frontal cortex approximately putamen <temporal cortex approximately cingulate <thalamus) and thus provided reliable indices of MAO-A density. Total distribution volume (DV) values were also highly stable and not different from those estimated with the Logan approach. Fixing the DV of free and nonspecifically bound radiotracer (DV(F + NS)) or coupling DV(F + NS) between brain regions enabled more stable estimates of k(3)/k(4) as compared with an unconstrained 2CM. Moclobemide treatment leads to a 64% to 79% MAO-A blockade across brain regions, a result that supports the specificity of [(11)C]-harmine binding to MAO-A. The stability and reliability of DV(B) values obtained from an unconstrained 2CM, together with the computational simplicity associated with this method, support the use of DV(B) as an appropriate outcome measure for [(11)C]-harmine. These results indicate the suitability of using [(11)C]-harmine for quantitative evaluation of MAO-A densities using PET and should enable further studies of potential MAO-A dysregulation in several psychiatric and neurologic illnesses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16079787     DOI: 10.1038/sj.jcbfm.9600197

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  32 in total

Review 1.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 2.  Is there a genetic contribution to cultural differences? Collectivism, individualism and genetic markers of social sensitivity.

Authors:  Baldwin M Way; Matthew D Lieberman
Journal:  Soc Cogn Affect Neurosci       Date:  2010-06       Impact factor: 3.436

3.  Noninvasive blood-free full quantification of positron emission tomography radioligand binding.

Authors:  Francesca Zanderigo; R Todd Ogden; Ramin V Parsey
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-05       Impact factor: 6.200

4.  [11C]Harmine Binding to Brain Monoamine Oxidase A: Test-Retest Properties and Noninvasive Quantification.

Authors:  Francesca Zanderigo; Alexandra E D'Agostino; Nandita Joshi; Martin Schain; Dileep Kumar; Ramin V Parsey; Christine DeLorenzo; J John Mann
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

5.  MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding.

Authors:  Allan K Hansen; David J Brooks; Per Borghammer
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

6.  In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism.

Authors:  Suzan Owaisat; Robert B Raffa; Scott M Rawls
Journal:  Neurosci Lett       Date:  2012-08-03       Impact factor: 3.046

7.  Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms.

Authors:  Lina Chiuccariello; Sylvain Houle; Laura Miler; Robert G Cooke; Pablo M Rusjan; Grazyna Rajkowska; Robert D Levitan; Stephen J Kish; Nathan J Kolla; Xiaoming Ou; Alan A Wilson; Jeffrey H Meyer
Journal:  Neuropsychopharmacology       Date:  2013-10-24       Impact factor: 7.853

8.  In vivo quantification of monoamine oxidase A in baboon brain: a PET study using [(11)C]befloxatone and the multi-injection approach.

Authors:  Michel Bottlaender; Héric Valette; Jacques Delforge; Wadad Saba; Ilonka Guenther; Olivier Curet; Pascal George; Frédéric Dollé; Marie-Claude Grégoire
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-18       Impact factor: 6.200

9.  Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.

Authors:  Joanna S Fowler; Jean Logan; Albert J Azzaro; Robert M Fielding; Wei Zhu; Amy K Poshusta; Daniel Burch; Barry Brand; James Free; Mahnaz Asgharnejad; Gene-Jack Wang; Frank Telang; Barbara Hubbard; Millard Jayne; Payton King; Pauline Carter; Scott Carter; Youwen Xu; Colleen Shea; Lisa Muench; David Alexoff; Elena Shumay; Michael Schueller; Donald Warner; Karen Apelskog-Torres
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

10.  Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies.

Authors:  Junchao Tong; Jeffrey H Meyer; Yoshiaki Furukawa; Isabelle Boileau; Li-Jan Chang; Alan A Wilson; Sylvain Houle; Stephen J Kish
Journal:  J Cereb Blood Flow Metab       Date:  2013-02-13       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.